RxDoctor Payments DataLook up a doctor →

Pravinchandra Patel, MD

Gastroenterology · Columbus, GANPI 1326055609

Payments from drug & device makers

$97,409in general payments, 2019–2025

Across 502 payments — averaging $194.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$31K
  • Takeda Pharmaceuticals U.S.A., Inc.$31K
  • Gilead$28K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$454
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,50598%
  • Education$1712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,409 in reported general payments places this provider in the 90th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$151,633
Medicare patients
608
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide160$126,491
CreonLipase/Protease/Amylase15$59,472
TrulancePlecanatide11$8,262
Sucralfate129$7,463
Pantoprazole Sodium514$5,217
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C26$3,638
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg120$2,528
Lubiprostone15$2,324
Esomeprazole Magnesium37$1,833
Omeprazole151$1,679
Budesonide EcBudesonide11$1,644
Lactulose13$1,053
Lansoprazole14$909
Dicyclomine Hcl41$791
Famotidine32$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,396$185,962175 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$1,121$11,90037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →